PR Newswire
SAN DIEGO and PENNINGTON, N.J., March 27, 2019
SAN DIEGO and PENNINGTON, N.J., March 27, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that the Company will host a Key Opinion Leader (KOL) Symposium focused on the potential of TAVO™ (tavokinogene telseplasmid), its lead immunotherapy investigational product candidate, on Friday, April 5, 2019 at 8:00 a.m. ET in New York City.
The KOL Symposium will feature a keynote presentation from Adil Daud, M.D., the Lead U.S. Investigator for KEYNOTE-695 and Clinical Professor of Medicine and Dermatology at University of California, San Francisco (UCSF), and Director of Melanoma Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center.
Among other important topics, Dr. Daud's presentation will:
Following Dr. Daud's presentation, OncoSec's management team will:
The FDA designated Fast Track Development Program status to OncoSec's TAVO™ in combination with KEYTRUDA® to stop or cause the regression of the tumor of patients with Stage III/IV melanoma who are progressing on either KEYTRUDA® or OPDIVO®. A drug that receives Fast Track designation is eligible for Accelerated Approval, if relevant criteria are met.
A live webcast of the event will be available. To access the live webcast, please visit the Investor Relations section of OncoSec's website at ir.oncosec.com. An archived replay of the webcast will also be available at the same location.
About OncoSec Medical Incorporated and TAVO™
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy investigational product candidate – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its ImmunoPulse® platform. For more information, please visit www.oncosec.com.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
OPDIVO® is a registered trademark of Bristol-Myers Squibb.
ImmunoPulse® is a registered trademark of OncoSec Medical Incorporated.
CONTACT
Investor Relations:
Will O'Connor
Stern Investor Relations
(212) 362-1200
[email protected]
Media Relations:
Katie Dodge
JPA Health Communications
(617) 657-1304
[email protected]
View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-to-host-key-opinion-leader-symposium-on-april-5-2019-300819397.html
SOURCE OncoSec Medical Incorporated
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member